In a similar report by Mercer et al. [34], assessed the risk for NMSC in a cohort of 15,000 RA patients that were treated with either anti-TNF or non-biological disease-modifying antirheumatic drugs (nbDMARD). The gene discussed is TNF; the disease is rheumatoid arthritis.